Natacha Comandante-Lou

The paper analyzes microglial communication in Alzheimer's disease using single-nucleus RNA sequencing to identify altered signaling pathways and cell interactions associated with disease pathology.

The paper identifies two genes, ADRA1B and LY6E-DT, downregulated in excitatory neurons associated with neuroticism and found to partially mediate the risk of Alzheimer's disease.

This study identifies BAG3's role in astrocytic proteostasis in Alzheimer's disease by showing its interactions with autophagy, proteasome, and retromer components, and its impact on Aβ clearance.

The paper identifies a novel astrocyte state linked to cognitive decline in Alzheimer's disease and validates its regulators through multi-modal analysis and mechanistic experiments.

The paper uses HDAC inhibitors to mimic human DAM in vitro and identifies shared marker genes.

The paper examines immunosenescence trajectories in diverse populations, finding associations between immunological age and brain atrophy, while highlighting CMV status and genetic ancestry as key factors.

This paper develops a mathematical model of drug-induced resistance that fits experimental data and identifies optimal dosing strategies to minimize tumor cell volume.

The paper identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer's disease by characterizing their effects on human microglial subtypes in vitro and in a zebrafish model.

The paper shows that the AP-1 transcription factor network explains cellular plasticity in melanoma by regulating differentiation states and responses to MAPK inhibitors.

This paper introduces probabilistic phenotype metrics to assess drug efficacy and combination effectiveness by analyzing single-cell responses, showing they reduce bias and improve sensitivity to heterogeneity.